Replies to post #10438 on Biotech Values

[DewDiligence]

>>But I see that you mention a theory that they can reduce or eliminate patient antibodies in biologics (relative to conventional methods I presume) - on what basis does this theory exist ?<<

io: That would be nice, but I didn’t say that and I don’t think Urche did (although he can speak for himself).

We do know that none of the 200+ patents treated with ATryn has developed anti-ATryn antibodies. However, this merely means that anti-ATryn antibody formation should become a non-issue – it does not mean that ATryn is superior to plasma-based antithrombin on this score.

The reason that ATryn is safer than plasma-based antithrombin is that ATryn carries no risk of transmitting pathogens that can be carried in human blood. Regards, Dew

p.s. Also see #msg-4988136.